Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00757250 · ClinicalTrials.gov registry record · Phase 1
Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy
A Phase 1 study, sponsored by US Biotest.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00757250 is a Phase 1 study that was terminated before completion, run by US Biotest. The registered enrollment target is 13 participants.
The verdict
NCT00757250, a Phase 1 study, was terminated before completion, sponsored by US Biotest.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of an investigational medication, TXA127, and its ability to increase T-lymphocyte counts, specifically CD4+ T-lymphocytes, in persons infected with human immunodeficiency virus who are taking highly active anti-retroviral therapy.
Interventions
- DRUG Angiotensin 1-7
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00757250
The ClinicalTrials.gov registry entry for NCT00757250 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Biotest, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Angiotensin 1-7 is the first listed.
NCT00757250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00757250 about?
NCT00757250 is a clinical study titled "Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy". The purpose of this study is to test the safety of an investigational medication, TXA127, and its ability to increase T-lymphocyte counts, specifically CD4+ T-lymphocytes, in persons infected with human immunodeficiency virus who are taking highly active anti-retroviral therapy.
What is the current status of trial NCT00757250?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2008-09. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00757250?
The interventions under investigation include: Angiotensin 1-7 (DRUG).
Who is sponsoring clinical trial NCT00757250?
This trial is sponsored by US Biotest, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.